Building on the promise of cancer vaccines for solid tumors.
A novel telomerase vaccine (INVAC-1) has been evaluated in a phase I clinical trial. It induced CD8+ and CD4+ T cell responses and reduced circulating regulatory T cells. The findings support further development, especially in combination with vaccine adjuvants, plus therapies to increase immune infiltrates into solid tumor metastases.